secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2024-12-06T23:59:59+00:00
Accession:  0001411685-24-000059
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen posts new corporate presentation; no specific financial updates
------------------------------------------------------------------------

- Company released an updated corporate presentation on December 6, 2024.
- Tagline: 'Pioneering neuroscience with nose-to-brain neurocircuitry'.
- No new financial guidance, clinical results, or material transactions disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000141168524000059/0001411685-24-000059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000141168524000059/vtgn-20241206.htm
  HTML page:      https://secwatch.observer/filing/0001411685-24-000059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer